After this period, your provider may recommend: A 1-2 month break before resuming Continued treatment with periodic monitoring Dose adjustments based on your response Long-term use beyond 6 months should include periodic lab testing (IGF-1 levels, metabolic panel) and provider evaluation
10-O-(N, N-dimethylaminoethyl) ginkgolide B methanesulfonate (XQ-1H) has been shown to normalize the expression of claudin-5, occludin, ZO-1, and -catenin in ischemic stroke model mice, leading to reduced BBB permeability and protection against oxygenglucose deprivation/reoxygenation injuries [292]
When people are saying we don't know how it works, then they refer to the animal studies because there are actually so many places that GLP-1 works in the brain
We conduct a thorough health assessment before any treatment to ensure it's appropriate for you
Additionally, it may reduce insulin resistance by lowering insulin levels and supporting better glucose metabolism